HAYA Therapeutics
PrivateLast Round
Series A
May 8, 2025
Total Funding Raised
$91.79M
Company Overview
HAYA Therapeutics is a biotechnology company developing programmable therapeutics targeting regulatory RNAs to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HAYA Therapeutics Comparables
Compare HAYA Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Therorna Inc. | 78% | |
| Eclipsebio | 77% | |
| Harness Therapeutics | 77% | |
HAYA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 8, 2025 | ||||
| Grant | Feb 12, 2025 | ||||
| Seed | Feb 9, 2022 | ||||
| Seed | May 20, 2021 | ||||
| Grant | Aug 16, 2018 | ||||
Grant | Feb 2, 2018 |
Key People
Founding team and executive leadership
HAYA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LifeLink Ventures | Series A |
| 4see ventures | Seed, Series A |
| +ND Capital | Series A |
| Viva BioInnovator | Seed |
| Humboldt Fund | Seed |
| Athos Capital | Series A |
| Viva Biotech | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Lead program HTX-001 advancing for hypertrophic cardiomyopathy treatment.
- Oct 1, 2025
Received the Innosuisse Certificate for Sustainable Growth.
HAYA Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about HAYA Therapeutics's valuation, stock price, and market status.